Repligen (NASDAQ:RGEN) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research note published on Wednesday.

Other analysts have also issued research reports about the company. Stephens restated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Wells Fargo & Company initiated coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Finally, UBS Group reduced their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Up 1.3 %

RGEN stock opened at $150.47 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The stock has a market capitalization of $8.43 billion, a P/E ratio of -406.66, a P/E/G ratio of 4.27 and a beta of 0.96. The business has a 50-day moving average of $141.59 and a 200-day moving average of $144.78. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the firm posted $0.23 earnings per share. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Repligen will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RGEN. QRG Capital Management Inc. increased its stake in shares of Repligen by 31.2% in the first quarter. QRG Capital Management Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $658,000 after buying an additional 850 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Repligen by 5.2% in the first quarter. Russell Investments Group Ltd. now owns 35,134 shares of the biotechnology company’s stock valued at $6,463,000 after buying an additional 1,746 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of Repligen by 4.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 64,035 shares of the biotechnology company’s stock valued at $10,781,000 after buying an additional 2,520 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Repligen by 30.2% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock valued at $5,312,000 after buying an additional 6,705 shares during the period. Finally, Nicolet Advisory Services LLC increased its stake in shares of Repligen by 55.4% in the first quarter. Nicolet Advisory Services LLC now owns 2,249 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 802 shares during the period. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.